Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Early scan hopes to predict cervical cancer outcomes

NCT ID NCT01641484

Knowledge-focused Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether MRI and PET scans taken two weeks into radiotherapy can predict if cervical cancer will be controlled. Researchers measured tumor size and activity in 9 patients with stage I to IIIB cervical cancer. The goal was to find early signs of treatment failure, but the study was stopped early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify early which patients need more aggressive treatment for cervical cancer.
What could go wrong
The study was terminated early with only 9 participants, so results are very limited and may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

9 people

The number who actually took part.

Started

Jan 2012

Finished

Feb 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * cervix epidermoid cancer or adenocarcinoma : I to IIIB * treatment by radiochemotherapy * ECOG ≤ 1 * social and psychological compliance for standard treatment of radiochemotherapy for cervix carcinoma * patient affiliated to health insurance system * signed informed consent Exclusion Criteria : * contraindication to chemoradiotherapy * resequable cervical cancer * para-aortic metastases histologically proven * inability to perform an abdominal MRI or a PET Scan * contraindications related to MRI: pacemaker, vascular clip, and all devices incompatible with the electromagnetic field generated by MRI * unbalanced diabete * administration of EPO * transfusion within 3 days before the first biopsy * creatinine clearance under 60 mL / min; * ANC \<1500 / mm3 and Platelets \<120,000 / mm3 * neuropathy, diabetes (fasting glucose greater than 140 mg / l) or any other condition that strongly contraindicates concomitant chemotherapy with radiotherapy * sigmoid diverticulitis, Crohn's disease or systemic disease, collagenose

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervix cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical carcinoma neoplasm Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervix cancer Oncology

Contacts and locations

Locations

  • Oscar Lambret Center

    Lille, 59020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.